Hypertension in adults (update) Committee meeting 4

24/01/2018 Date:

Linacre Room, Royal College of Physicians, 11 St Andrew's Place, London NW1 4LE Location:

Minutes: Confirmed NICE National Institute for Health and Care Excellence

Committee members present:	
Anthony Wierzbicki (Chair)	(Present for notes 1–5)
Liz Clark	(Present for notes 1–5)
Elizabeth Denver	(Present for notes 1–5)
Mark Glover	(Present for notes 1–5)
Judith Magowan	(Present for notes 1–5)
Terry McCormack	(Present for notes 1–5)
Irene McGill	(Present for notes 1–5)
Richard McManus	(Present for notes 1–5)
Lucy Pollock	(Present for notes 1–5)
Mark Shapley	(Present for notes 1–5)
Alison Warren	(Present for notes 1–4C)

In attendance:		
Catherine Baden-Daintree	Senior Medical Editor, NICE	(Present for notes 1–5)
Caroline Kier	Guideline Commissioning Manager, NICE	(Present for notes 1–5)
Jane Lynn	Business Analyst, NICE	(Present for notes 1–5)
Rebecca Boffa	Research Fellow, NGC	(Present for notes 1–5)
Serena Carville	Guideline Lead, NGC	(Present for notes 1–5)
Margaret Constanti	Senior Health Economist, NGC	(Present for notes 1–5)
Meredith Faust	Project Manager, NGC	(Present for notes 1–5)
Beatriz Ferrer-Quiles	Information Specialist, NGC	(Present for notes 4D– 4E)
Christopher Floyd	Clinical Trainee, NGC	(Present for notes 1–5)
Qudsia Malik	Senior Research Fellow, NGC	(Present for notes 1–5)

Apologies:	
Bryan Williams	Committee member

1. Welcome and objectives for the meeting

The Chair welcomed the committee members and attendees to the fourth meeting on Hypertension in adults. The committee members and attendees introduced themselves.

No members of the public asked to observe the meeting.

The Chair informed the committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included an evidence review on measuring blood pressure to diagnose adults with suspected primary hypertension and finalising the malignant hypertension, outcome improvement targets and the optimum blood pressure or cardiovascular risk targets protocols.

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was measuring blood pressure to diagnose adults with suspected primary hypertension, malignant hypertension, outcome improvement targets and optimum blood pressure or cardiovascular risk targets.

The Chair asked everyone to declare verbally any interests that have arisen since the last meeting. There were no new interests declared.

The Chair and a senior member of the Developer's team noted that the following members would not participate in a part of the meeting:

 Richard McManus should withdraw from making recommendations for the review question 'In adults with suspected primary hypertension, what is the best method of measuring blood pressure (home, ambulatory or clinic measurement) to establish the diagnosis and predict cardiovascular events?' due to conducting research in this area.

3. Minutes of last meeting

The Chair asked the committee if it wanted any changes made to the minutes of the last meeting. The committee agreed that the minutes were a true and accurate account of the meeting.

The Chair confirmed that all matters arising had been completed or were in hand.

4. Questions and discussion

- A. Catharine Baden-Daintree, Senior Medical Editor at NICE, gave a presentation on making clear and helpful recommendations. The committee asked questions following her presentation.
- B. Rebecca Boffa, Research Fellow at the NGC, presented the clinical evidence for the review question: In adults with suspected primary hypertension, what is the best method of measuring blood pressure (home, ambulatory or clinic measurement) to establish the diagnosis and predict cardiovascular events? The committee asked questions about the clinical evidence.
- C. Margaret Constanti, Senior Health Economist at the NGC, presented the economic evidence for the review question: In adults with suspected primary hypertension, what is the best method of measuring blood pressure (home, ambulatory or clinic measurement) to establish the diagnosis and predict cardiovascular events? The committee asked questions about the economic evidence.
- D. Qudsia Malik, Senior Research Fellow at the NGC, led a discussion on finalising the following protocols:
 - 3.2 Use of targets to diagnose hypertension
 - 3.3 Which targets to use to diagnose hypertension
 - 6.1 Malignant hypertension

The committee discussed the protocols.

- E. Jane Lynn, Business Analyst at NICE, gave a presentation on resource impact assessments. The committee asked questions following her presentation.
- F. Margaret Constanti led a discussion on the prospective health economic model for review question 3.1: At what blood pressure or cardiovascular disease risk threshold should antihypertensive drug treatment be initiated? The committee discussed the prospective economic model and its thresholds.

5. Any other business

None.

Date of next meeting: 28/02/2018

Location of next meeting: NGC Boardroom, Royal College of Physicians, 11 St

Andrew's Place, London NW1 4LE